Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Single-arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia

Next Previous
X
Search
Trial Profile

A Multicenter, Open-label, Single-arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obinutuzumab (Primary) ; Bendamustine; Chlorambucil; Cyclophosphamide; Cyclophosphamide; Fludarabine; Fludarabine
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Registrational
  • Acronyms GREEN
  • Sponsors Roche

    • Most Recent Events

    • 06 Nov 2019 Results released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 26 Oct 2018 Status changed from active, no longer recruiting to completed.
    • 22 Oct 2018 The trial has been completed in Ireland.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top